文献速递骨质疏松与钙磷/甲状旁腺

2011至2022年美国商业保险与联邦医疗保险优势计划参保者骨质疏松药物治疗接受趋势

Trends in Osteoporosis Drug Therapy Receipt Among Commercial and Medicare Advantage Enrollees in the United States, 2011-2022.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该回顾性分析基于OptumLabs数据仓库2011至2022年≥50岁商业保险或联邦医疗保险优势计划参保者的患者-季度观察,描述骨质疏松药物治疗(ODT)使用趋势。结果显示,有记录骨质疏松的女性ODT填充率上升但仍低,无记录骨质疏松的脆性骨折女性ODT填充率下降,提示骨质疏松诊断不足导致治疗不足。

要点

  • 超过70%的脆性骨折患者没有骨质疏松的记录诊断。
  • ≥65岁有记录骨质疏松且无脆性骨折的女性,ODT填充率从2011年36.3%升至2022年50.1%(P < .001)。
  • ≥65岁有记录骨质疏松且有脆性骨折的女性,ODT填充率从2011年30.8%升至2022年43.7%(P < .001)。

核心结论

  • 有记录骨质疏松的患者ODT使用增加但仍低;无记录骨质疏松的脆性骨折患者ODT使用率低,提示骨质疏松诊断不足导致ODT使用不足。

研究设计与样本

  • 回顾性分析2011至2022年OptumLabs数据仓库中≥50岁商业保险或联邦医疗保险优势计划参保者的患者-季度观察,共166 673 420个患者-季度观察。
  • 主要结局为按年龄、性别、脆性骨折和记录骨质疏松分层的患者-季度观察中ODT使用的比例,采用Cuzick检验评估趋势。

主要发现

  • 超过70%的脆性骨折患者没有骨质疏松的记录诊断。
  • ≥65岁有记录骨质疏松且无脆性骨折的女性,ODT填充率从2011年36.3%升至2022年50.1%(P < .001)。
  • ≥65岁有记录骨质疏松且有脆性骨折的女性,ODT填充率从2011年30.8%升至2022年43.7%(P < .001)。
  • 有脆性骨折但无记录骨质疏松的女性,ODT填充率从2011年9.2%降至2022年7.4%(P = .015)。
  • 50-64岁女性和男性中观察到类似趋势。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: A national assessment of osteoporosis drug therapy (ODT) use can inform the extent of underdiagnosis and undertreatment of osteoporosis. OBJECTIVE: The aim was to describe trends in ODT use by age, sex, fragility fracture, and documented osteoporosis. METHODS: This was a retrospective analysis of patient-quarter observations for adults aged ≥50 years with commercial or Medicare Advantage health insurance in the OptumLabs Data Warehouse between 2011 and 2022. The primary outcome was the proportion of patient-quarter observations with ODT use stratified by age, sex, fragility fracture, and documented osteoporosis. Cuzick tests were performed to assess trends ODT use. RESULTS: Analysis of 166 673 420 patient-quarter observations revealed that over 70% of patients with fragility fractures did not have documented osteoporosis. Among women aged ≥65 years with documented osteoporosis, ODT fill rates increased between 2011 and 2022 from 36.3% to 50.1% for women without fragility fractures (P < .001) and from 30.8% to 43.7% for women with fragility fractures (P < .001). However, ODT fill rates declined (9.2% to 7.4% between 2011 and 2022) for women with fragility fractures and no documented osteoporosis (P = .015). Similar trends were observed among women aged 50-64 years and men. CONCLUSION: ODT use for patients with documented osteoporosis has increased but remains low. Low rates of ODT use for patients with fragility fractures in the absence of documented osteoporosis suggests that underdiagnosis of osteoporosis contributes to underuse of ODTs.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Everhart AO, Brito JP, Clarke BL, et al. Trends in Osteoporosis Drug Therapy Receipt Among Commercial and Medicare Advantage Enrollees in the United States, 2011-2022. J Clin Endocrinol Metab. 2025. PMID: 39811927. doi:10.1210/clinem/dgae840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。